|
KMID : 0356419970150010065
|
|
Journal of Korean Andrology
1997 Volume.15 No. 1 p.65 ~ p.69
|
|
|
Prostaglandin El (Alprostadil) Intracavernosal Self-Injection Therapy in Erectile Dysfunction
|
|
Seong Bong-Mo
Kim Je-Jong
|
|
|
Abstract
|
|
|
Background : Intracavernosal self-injection is widely used as the first line therapy of erectile dysfunction. The principal drugs used are papaverine, phentolamine, and prostaglandine El (PGEI): other agents are phenoxybenzamine, thymoxamine, vasoactive intestinal polypeptide (VIP) and cyclic guanosine 3’,5’-monophosphate (cGRP) either as single agents or in combination. The reported low rates of drug-induced priapism and penile fibrosis have made PGE1 a papular choice for self-injection therapy.
Methods : We reviewed 65 patients with erectile dysfunction treated with PGE1 for more than 1 month between February 1996 and January 1997. The most common etiologies of erectile dysfunction were psychogenic (52 patients; 80%) and neurogenic (6 patients; 90%). The mean follow-up was 4.3 months and the mean dosage of PGE1 was
12.3 ㎍.
Results : At present, 30 patients are left in the self-injection treatment program, so the drop-out rate was 54%. The principal causes of drop-out were spontaneous recovery of erection (42%), dissatisfaction with the method (fear of needle; 23%), cost (11%), feeling that the method was ineffective (12%). The drop-out related to PGE1 complication (pain,
priapism) was 8%.
Conclusion : Intracarvemosal self-injection of PGE1 is a safe and very effective method of treatment for the patients with erectile dysfunction, although many patients drop out despite good clinical results.
|
|
|
KEYWORD
|
|
|
Impotence, Prostaglandin El, Intracarvernosal Self-Injection therapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|
|